Last reviewed · How we verify
Pre B-cell acute lymphoblastic leukemia
Approved treatments
- Besponsa · Pfizer
CD22-directed antibody-drug conjugate delivering cytotoxic calicheamicin to induce DNA breaks and apoptosis. - Blincyto · Amgen
Blincyto works by binding to both T cells and cancer cells, directing the T cells to kill the cancer cells.
Clinical guidelines
- FDA label — 2L
BESPONSA is indicated for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1 year and older.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Pre B-cell acute lymphoblastic leukemia patent landscape — cliff calendar, originator estates, attackable patents
- Pre B-cell acute lymphoblastic leukemia treatment landscape brief
- Pre B-cell acute lymphoblastic leukemia treatment updates RSS
Frequently asked questions about Pre B-cell acute lymphoblastic leukemia
What drugs treat Pre B-cell acute lymphoblastic leukemia?
Tracked treatments include Besponsa, Blincyto.
What is the treatment for Pre B-cell acute lymphoblastic leukemia?
Standard treatment for Pre B-cell acute lymphoblastic leukemia includes Besponsa, Blincyto. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Pre B-cell acute lymphoblastic leukemia?
FDA label publishes guidelines for Pre B-cell acute lymphoblastic leukemia. 1 guideline references tracked.
Related
- Treatment landscape: Pre B-cell acute lymphoblastic leukemia patent cliff · Pre B-cell acute lymphoblastic leukemia CI report
- Treatment: Besponsa · Pfizer
- Treatment: Blincyto · Amgen
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing